Where does Genzyme Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Genzyme Corporation ranks #1,332 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Genzyme Corporation hold?

Genzyme Corporation holds 317 US utility patents granted between 2015 and 2025, spanning 33 technology areas.

What is Genzyme Corporation's Innovation Score?

Genzyme Corporation has an Innovation Score of 57.8 out of 100 (top 5% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Genzyme Corporation focus on?

Genzyme Corporation's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 183 patents, ranking #74 of 6,058 assignees active in that subclass. Grants appear in 33 CPC subclasses total.

Is Genzyme Corporation's patent grant rate increasing or decreasing?

Genzyme Corporation's recent grant velocity is +12% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Genzyme Corporation's patents?

Genzyme Corporation's patents average 18.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Genzyme Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Genzyme Corporation

USPTO PatentsView assignee record - 317 granted patents across 33 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Genzyme ranks #1,332 of 49,997 tracked US assignees by granted-patent volume, with 317 patents across 33 technology areas.

#1,332
of 49,997 US assignees by volume: Top 5%
by Innovation Score (57.8/100): 18.8
avg claims per patent: +12%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1332 · US Corporation #1,332 · 317 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-MID 317 grants
TOP-DECILE #1,332/49,997
PHOTO-FINISH Harman Becker…
CPC-FOCUS A61P · 33 areas
INNOV-PAR 57.8/100
CLAIMS-RICH 18.8 claims/avg
TYPE-USCORP US Corporation
VEL-UP +12% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Harman Becker Automotive Systems GMBH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Genzyme’s 57.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 19.9 pts (34%) Velocity 6.4 pts (11%) Breadth 20.3 pts (35%) Claim depth 11.3 pts (20%)

Qualcomm Incorporated · highest

85
Carl Zeiss Industrie… · near

58
ClearOne · near

58
Genzyme · this assignee

58
RIKEN · near

58
Shanghai Dianba NEW… · near

58
3D Lighting… · lowest

7

What this shows Genzyme's Innovation Score is 57.8/100 (top 5% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Genzyme?

Each dot is one of Genzyme’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Genzyme’s own 18.8 claims/patent is ABOVE the 16.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Genzyme vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Genzyme's grants concentrate

Genzyme Corporation is a focused PatentsView assignee: 33 CPC subclasses with 57.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (39 grants) versus a trough of 20 in 2015. By volume, Genzyme sits between Itron, Inc. and University of Kansas.

Genzyme's three-year grant acceleration

From 2019–2021 to 2022–2024, Genzyme Corporation moved from 86 to 82 grants (0.95x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,312. See the growth leaderboard.

Itron

319
Kiekert

319
R J Reynolds Toba…

319
THE Chemours FC

319
Harman Becker Aut…

317
Massachusetts Mut…

317
Qisda

317
University of Kan…

317
Genzyme ◀

317

What this shows Genzyme holds 317 patents at rank #1,332, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Genzyme

By rank, the assignees closest to #1,332 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Genzyme's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Genzyme, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Genzyme ranks #74 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (58 here).

RIKEN 58 Carl Zeiss Industrielle Messtechnik GmbH 58 Shanghai Dianba NEW Energy Technology Co., Ltd. 58 ClearOne, Inc. 58

Similar claim depth

Nearest assignees by average claims per patent (18.8 here).

Corning Optical Communications LLC 18.8 avg 3shape A/S 18.8 avg Whitehead Institute For Biomedical Research 18.8 avg Idexx Laboratories Inc. 18.8 avg

Genzyme's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

58 Top 5% higher than 95% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Genzyme Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	20	6.3%
2016	21	6.6%
2017	36	11.4%
2018	20	6.3%
2019	28	8.8%
2020	24	7.6%
2021	34	10.7%
2022	23	7.3%
2023	20	6.3%
2024	39	12.3%
2025partial year	52	16.4%

Which technologies does Genzyme Corporation patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 183

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 174

C07K - Peptides 121

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 106

C07D - Heterocyclic Compounds 45

C12Y - Enzymes 45

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 37

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 30

B01D - Separation 25

C12M - Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Fermenters 21

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 19

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 10

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 10

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 8

A61B - DIAGNOSIS; SURGERY; Identification 8

Top 15 of 33 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Genzyme Corporation's patent record in context - here's where to go next.

Genzyme Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 57.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #1,332 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Genzyme Corporation against Itron, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 57.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.